Client Success
We leverage our unparalleled relationships across the life sciences ecosystem to connect the right leaders with the right companies.
Recent Client Success
Filter by placement
VP|October 20, 2025
SVP, Head of Clinical Development & Medical Affairs
Client Team Lead:
Client: Abeona Therapeutics Inc.
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of…
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the appointment of James A. Gow, MD, MBA, MS, MHCM, as the Senior Vice President, Head of…
CCO|September 22, 2025
Chief Commerical Officer
Client Team Lead:
Client: ArriVent
ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent…
ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Brent S. Rice as Chief Commercial Officer (CCO). Mr. Rice joins ArriVent…
Director|August 14, 2025
Board of Directors
Client Team Lead:
Client: Abeona
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug…
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Bernhardt G. Zeiher, MD, FCCP, FACP, and Eric Crombez, MD as new independent members to its Board of Directors. Dr. Zeiher brings more than 20 years of drug…
Director|June 24, 2025
Board of Directors
Client Team Lead:
Client: Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD).
Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as…
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD).
Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as…
Director|April 28, 2025
Board of Directors
Client Team Lead:
Client: ArriVent
ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings…
ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D., Ph.D. to its Board of Directors. Dr. Parsey brings…
CFO|February 26, 2025
Chief Financial Officer
Client Team Lead:
Client: CORXEL
Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today announced the appointment of Kevin Xie, PhD, as Chief Financial Officer. Kevin brings over…
Corxel Pharmaceuticals (CORXEL), a leading biotech company committed to bringing innovative science and medicines to underserved patients with cardiometabolic diseases around the world, today announced the appointment of Kevin Xie, PhD, as Chief Financial Officer. Kevin brings over…
Partner|January 27, 2025
Partner
Client Team Lead:
Client: LightSpeed
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, Health, and Fintech sectors.
Today I’m joining Lightspeed, as a Partner to lead Healthtech investing.
I started on…
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, Health, and Fintech sectors.
Today I’m joining Lightspeed, as a Partner to lead Healthtech investing.
I started on…
CMO|November 25, 2024
Chief Medical Officer
Client Team Lead:
Client: AffyImmune Therapeutics
AffyImmue Therapeutics, a clinical-stage biotechnology company committed to developing its novel, first-in-class ICAM-1 targeting chimeric antigen receptor (CAR) T cell therapy for solid tumors, today announced the appointment of Deyaa Adib, M.D., as Chief Medical Officer (CMO).…
AffyImmue Therapeutics, a clinical-stage biotechnology company committed to developing its novel, first-in-class ICAM-1 targeting chimeric antigen receptor (CAR) T cell therapy for solid tumors, today announced the appointment of Deyaa Adib, M.D., as Chief Medical Officer (CMO).…
CEO|November 19, 2024
Chief Executive Officer
Client Team Lead:
Client: ArrePath, Inc.
ArrePath, Inc., an emerging biotechnology company focused on applying deep phenotypic insights and machine learning to the discovery of new anti-infectives, today announced the appointment of Kevin Krause as President and Chief Executive. Mr. Krause brings more…
ArrePath, Inc., an emerging biotechnology company focused on applying deep phenotypic insights and machine learning to the discovery of new anti-infectives, today announced the appointment of Kevin Krause as President and Chief Executive. Mr. Krause brings more…
Learn More About Our Search Opportunities
Need help finding the right opportunity? We'll be happy to help!